Thoracic Cancer 2021 April 8 [Link] Kageaki Watanabe, Yusuke Okuma, Shoko Kawai, Makoto Nagamata, Yukio Hosomi Abstract Background: Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next-generation anthracycline that is commonly used to…

Read More

Future Oncology 2021 March 26 [Link] David M Waterhouse, Esmond D Nwokeji, Marley Boyd, John R Penrod, Janet L Espirito, Nicholas J Robert, Melinda J Daumont Abstract Aim: To assess real-world treatment patterns and outcomes among patients with advanced malignant pleural mesothelioma. Patients & methods: Retrospective database analysis. Results: In all, 469 patients received first-line…

Read More

BMC Cancer 2021 March 20 [Link] Rui Kitadai, Tatsunori Shimoi, Kazuki Sudo, Emi Noguchi, Yusuke Nagata, Ryoichi Sawada, Atsuo Takashima, Narikazu Boku, Kan Yonemori Abstract Background: Standard treatment for malignant peritoneal mesothelioma has not been established, and systemic chemotherapy is administered according to malignant pleural mesothelioma. We previously reported the efficacy of cisplatin plus pemetrexed…

Read More

European Journal of Pharmaceutical Sciences 2021 March 2 [Link] Aurélie Lombard, Hitesh Mistry, Sonya C Chapman, Ivelina Gueorguieva, Leon Aarons, Kayode Ogungbenro Abstract In the last update of the RECIST criteria in 2009, it was proposed that the number of target lesions to be followed over time for response-to-treatment assessment be reduced from 10 to…

Read More

European Journal of Pharmaceutical Sciences 2021 March 2 [Link] Aurélie Lombard, Hitesh Mistry, Sonya C Chapman, Ivelina Gueorguieva, Leon Aarons, Kayode Ogungbenro Abstract In the last update of the RECIST criteria in 2009, it was proposed that the number of target lesions to be followed over time for response-to-treatment assessment be reduced from 10 to…

Read More

Thoracic Cancer 2021 March 4 [Link] Jordi Guzmán-Casta, Sonia Carrasco-CaraChards, Jorge Guzmán-Huesca, Carla Paola Sánchez-Ríos, Rodrigo Riera-Sala, José Fabián Martínez-Herrera, Erika Sagrario Peña-Mirabal, Diana Bonilla-Molina, Jorge Arturo Alatorre-Alexander, Luis Manuel Martínez-Barrera, Jerónimo Rafael Rodríguez-Cid Abstract Background: Malignant pleural mesothelioma is an infrequent neoplasia with a poor prognosis and the majority of patients already have advanced…

Read More

Cancer Treatment and Research Communications 2021 February 24 [Link] Xiaomin Niu, Chenglei Zhou, Aiyan Hu, Lingzi Su, Dan Lin, Hui Han, Yan Lu Abstract Synchronous malignant mesothelioma (MM) and lung carcinoma are extremely rare in patients without a history of asbestos exposure and poses tremendous difficulties in clinical management. We report a patient without asbestos…

Read More

BMC Palliative Care 2021 February 26 [Link] Tine Ikander, Stefan Starup Jeppesen, Olfred Hansen, Mette Raunkiær, Karin Brochstedt Dieperink Abstract Background: When discussing treatment options and future care, it is important to understand the expectations of patients and family caregivers related to palliative chemotherapy and to identify patterns in patients’ quality of life. The study…

Read More

Lung Cancer 2021 January 14 [Link] Sharyn I Katz, Leonid Roshkovan, Ian Berger, Joseph S Friedberg, Evan W Alley, Charles B Simone 2nd, Andrew R Haas, Keith A Cengel, Daniel H Sterman, Steven M Albelda Abstract Objectives: Soluble mesothelin-related protein (SMRP) and fibulin-3 serum levels may serve as diagnostic and prognostic biomarkers of malignant pleural…

Read More

The Oncologist 2021 February 8 [Link] Chiho Miyagawa, Hisamitsu Takaya, Kazuko Sakai, Kazuto Nishio, Maho Konishi, Sachiko Minamiguchi, Toshihide Shimada, Noriomi Matsumura Abstract Recently, several malignant peritoneal mesothelioma (MPMs) that occur in young women without asbestos exposure and with fusion genes such as anaplastic lymphoma kinase (ALK) and Ewing sarcoma breakpoint region 1 (EWSR1) have…

Read More